In a research note released this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a $24 …
In a research report issued Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target, which represents a …
In a research report published August 14, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, following the company’s second-quarter results, burning …
In a research note released August 14, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following the company’s second-quarter results. Tekmira ended the quarter …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on StemCells Inc. (STEM), with a $5 price target, which represents a potential upside of 312% from …
In a research note released August 11, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, following the company’s second-quarter results. Inovio …
In a report issued August 5, Maxim Group analyst Jason Kolbert provided an optimistic view on Teva Pharmaceuticals (TEVA) following the release of the company’s second-quarter results, …
In a research note published yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Cesca Therapeutics (KOOL) with a $7 price target, on …
Maxim Group analyst Jason Kolbert provided an optimistic view on Omeros Corp. (OMER) heading into the company’s second-quarter earnings report, where it is …
In a research note issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following a report that created a buzz around Ebola drug …
